TY - JOUR
T1 - The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury
AU - Zhang, Bin
AU - Shi, Wei
AU - Ma, Juan
AU - Sloan, Alexis
AU - Faul, Christian
AU - Wei, Changli
AU - Reiser, Jochen
AU - Yang, Yun
AU - Liu, Shuangxin
AU - Wang, Wenjian
N1 - Funding Information:
Acknowledgments This work was supported by grants from the Guangdong Science & Technology Department and in part by grants from the National Institute of Health (DK073495 and DK089394 to Dr. Reiser). We thank Dr. P Mundel (Massachusetts General Hospital, Boston, USA) for providing conditionally immortalized mouse podocytes.
PY - 2012/12
Y1 - 2012/12
N2 - Circulating and podocyte-bound urokinase receptor (uPAR) is a mediator of podocyte injury, proteinuria, and focal segmental glomerulosclerosis (FSGS) allowing pathological activation of the uPAR-β3 integrin signaling axis. Clinically, calcineurin inhibitors (e.g., cyclosporine A, CsA) are known to suppress T cells, yet are also being used to reduce proteinuria in FSGS, suggesting the possibility of signal cross talk between uPAR and calcineurin. Calcineurin is known to facilitate the nuclear translocation of the nuclear factor of activated T cells (NFAT). Accordingly, in vivo conditional NFATc1 activation in podocytes leads to proteinuria in mice, yet the downstream targets of NFAT remain unclear. Here, we show that inducible podocyte-specific expression of constitutively active NFATc1 increased podocyte uPAR expression by binding to the Plaur gene promoter (encoding uPAR) in chromatin immunoprecipitation assays. Pathological uPAR signals in podocytes are independent of T cells and affect cell motility via activation, but not expression, changes of the β3 integrin and can be blocked by CsA, NFAT-siRNA, or the cell-permeable NFAT inhibitor (11R-VIVIT) using rodent models of glomerular disease (LPS; 5/6 nephrectomized rats). Taken together, these findings identify podocyte uPAR as a downstream target of NFAT and provide further insights into the pathogenesis of FSGS.
AB - Circulating and podocyte-bound urokinase receptor (uPAR) is a mediator of podocyte injury, proteinuria, and focal segmental glomerulosclerosis (FSGS) allowing pathological activation of the uPAR-β3 integrin signaling axis. Clinically, calcineurin inhibitors (e.g., cyclosporine A, CsA) are known to suppress T cells, yet are also being used to reduce proteinuria in FSGS, suggesting the possibility of signal cross talk between uPAR and calcineurin. Calcineurin is known to facilitate the nuclear translocation of the nuclear factor of activated T cells (NFAT). Accordingly, in vivo conditional NFATc1 activation in podocytes leads to proteinuria in mice, yet the downstream targets of NFAT remain unclear. Here, we show that inducible podocyte-specific expression of constitutively active NFATc1 increased podocyte uPAR expression by binding to the Plaur gene promoter (encoding uPAR) in chromatin immunoprecipitation assays. Pathological uPAR signals in podocytes are independent of T cells and affect cell motility via activation, but not expression, changes of the β3 integrin and can be blocked by CsA, NFAT-siRNA, or the cell-permeable NFAT inhibitor (11R-VIVIT) using rodent models of glomerular disease (LPS; 5/6 nephrectomized rats). Taken together, these findings identify podocyte uPAR as a downstream target of NFAT and provide further insights into the pathogenesis of FSGS.
KW - Calcineurin
KW - NFAT
KW - Podocyte
KW - suPAR
KW - uPAR
KW - β3 integrin
UR - http://www.scopus.com/inward/record.url?scp=84884211336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884211336&partnerID=8YFLogxK
U2 - 10.1007/s00109-012-0960-6
DO - 10.1007/s00109-012-0960-6
M3 - Article
AN - SCOPUS:84884211336
SN - 0946-2716
VL - 90
SP - 1407
EP - 1420
JO - Journal of Molecular Medicine
JF - Journal of Molecular Medicine
IS - 12
ER -